Gabapentin
Product Images NDC 69189-0683

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 69189-0683). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avera Mckennan Hospital, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 100 mg Capsule (6918906831)

Gabapentin 100 mg capsule label showing manufacturer as Avera McKennan Hospital, Sioux Falls, SD. The label includes manufacturing and expiration dates, hospital lot number, and NDC 69189-0683. The label is printed on a small white pouch or packet with minimal text and two QR codes.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

An equation illustrating the calculation for creatinine clearance (CLCr), incorporating factors such as age, weight, serum creatinine levels, and an adjustment multiplier for female patients.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph depicting mean pain scores over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis shows weeks from baseline to 8, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph depicting the mean pain score over a 7-week period for three groups: placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period, while the y-axis shows the mean pain score from 0 to 10. Pain scores decrease over time for both gabapentin groups compared to placebo.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing response proportions in two studies. Study 1 compares placebo (12%) and gabapentin 3600 mg (29%). Study 2 compares placebo (14%) with gabapentin 1800 mg (32%) and 2400 mg (34%). Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot chart showing the relationship between daily dose (mg) on the x-axis and difference (%) on the y-axis. The chart compares results for three studies labeled as STUDY a, STUDY b, and STUDY c using different colored square markers. Dose values range approximately from 600 to 1800 mg, and difference percentages range approximately from 2% to 22%.*

FDA Label Image

Gabapentin Structure (Gabapentin Struc)

Chemical structure of gabapentin showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxyl group (CH2CO2H). This molecular diagram represents the active ingredient gabapentin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.